Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NYMALIZE vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NMDA receptor antagonist; acts as a neuroprotective agent by reducing excitotoxicity and modulating calcium influx. Also binds to sigma-1 receptors, possibly contributing to neuroprotection.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
FDA-approved for the treatment of agitation associated with schizophrenia and bipolar I disorder (maintenance therapy). Off-label: treatment of agitation in Alzheimer's disease and other dementias, major depressive disorder (adjunct), obsessive-compulsive disorder, and other psychiatric conditions.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
10 mg (5 m L) intravenously over 5-15 minutes, may repeat after 15 minutes if needed; followed by continuous infusion of 0.9-2.0 mg/hour (5-10 m L/hour).
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Terminal elimination half-life is approximately 8–9 hours (range 5–12 hours) in patients with subarachnoid hemorrhage. In elderly or hepatically impaired patients, half-life may be prolonged. Clinically, steady-state is achieved after 3–5 days of oral dosing.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6; forms active metabolites (e.g., dextrorphan and 3-methoxymorphinan).
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Nymalize (nimodipine) is primarily eliminated via hepatic metabolism. Approximately 50% of the dose is excreted in urine as metabolites and <1% as unchanged drug. Fecal excretion accounts for ~20% of metabolites. Less than 1% is excreted unchanged in bile. Renal clearance is negligible for parent compound.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Nimodipine is 97–99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
92-98% bound to plasma proteins (primarily albumin)
Volume of distribution is approximately 0.8–1.6 L/kg. This large Vd indicates extensive tissue distribution, including penetration into the brain (cerebrospinal fluid concentrations are about 10% of plasma levels).
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral bioavailability is approximately 13% (range 3–30%) due to extensive first-pass hepatic metabolism. Intravenous administration yields 100% bioavailability.
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
No dose adjustment required for renal impairment; not removed by hemodialysis.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Child-Pugh B or C: reduce dose by 50%; consider alternative therapy in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not approved for pediatric use; safety and efficacy not established.
Not recommended for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment; monitor for hypotension due to age-related decreased baroreceptor sensitivity.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
No FDA black box warning.
No FDA black box warning.
Risk of abuse, dependence, and withdrawal; may cause cognitive and motor impairment; contraindicated in combination with other NMDA antagonists; use caution in patients with respiratory depression, severe hepatic impairment, or recent myocardial infarction.
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Hypersensitivity to the drug; concomitant use with other NMDA antagonists (e.g., ketamine, methoxetamine); monotherapy for schizophrenia; severe hepatic impairment (Child-Pugh class C).
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Grapefruit juice increases nimodipine plasma concentrations by inhibiting CYP3A4 metabolism, potentially leading to toxicity. Avoid grapefruit products entirely. Alcohol may exacerbate hypotension and dizziness. No other significant food interactions.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
First trimester: Cases of metabolic acidosis and respiratory depression in the neonate have been reported with intravenous nimodipine during pregnancy; however, oral nimodipine (NYMALIZE) lacks adequate studies. Second and third trimesters: Potential for maternal hypotension and reduced uteroplacental perfusion. Overall, nimodipine is an FDA Pregnancy Category C drug. Use only if potential benefit justifies risk to the fetus.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Nimodipine is excreted in human milk. The M/P ratio is not established. Due to potential for serious adverse reactions in nursing infants, discontinue breast-feeding or discontinue drug, taking into account the importance of the drug to the mother.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
No specific pharmacokinetic studies in pregnancy. Due to increased plasma volume and clearance, higher doses may be needed to achieve therapeutic levels; however, no established dosing guidelines. Use lowest effective dose and monitor clinical response and blood pressure.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
Nymalize (nimodipine) is a calcium channel blocker used specifically to prevent vasospasm following subarachnoid hemorrhage (SAH). It must be administered via nasogastric tube if the patient has impaired swallowing or is intubated. Monitor blood pressure closely due to risk of hypotension. Enteral administration is preferred over IV; if IV is used, avoid PVC tubing as nimodipine adsorbs to PVC. Do not administer with grapefruit juice.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Take this medication exactly as prescribed, even if you feel well.,If you cannot swallow the capsule, the liquid can be extracted using a needle and taken orally or via feeding tube.,Do not consume grapefruit or grapefruit juice while taking this medication.,Avoid alcohol as it may increase dizziness or hypotension.,Sit up slowly from lying or sitting position to prevent dizziness from low blood pressure.,Store capsules at room temperature away from light and moisture.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NYMALIZE vs AFEDITAB CR, answered by our medical review team.
NYMALIZE is a Calcium Channel Blocker that works by NMDA receptor antagonist; acts as a neuroprotective agent by reducing excitotoxicity and modulating calcium influx. Also binds to sigma-1 receptors, possibly contributing to neuroprotection.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NYMALIZE and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NYMALIZE is: 10 mg (5 m L) intravenously over 5-15 minutes, may repeat after 15 minutes if needed; followed by continuous infusion of 0.9-2.0 mg/hour (5-10 m L/hour).. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NYMALIZE and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NYMALIZE is classified as Category C. First trimester: Cases of metabolic acidosis and respiratory depression in the neonate have been reported with intravenous nimodipine during pregnancy; however, oral nimodipine (NY. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.